Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 19 November, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo

Nath Bio-Genes (India) Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: November 19, 2024, 6:44 pm

Market Cap 337 Cr.
Current Price 178
High / Low264/167
Stock P/E8.33
Book Value 339
Dividend Yield1.13 %
ROCE6.85 %
ROE6.23 %
Face Value 10.0
PEG Ratio-1.95

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Nath Bio-Genes (India) Ltd

Competitors of Nath Bio-Genes (India) Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Genomic Valley Biotech Ltd 30.1 Cr. 98.5107/22.4116 12.50.00 %0.57 %0.57 % 10.0
Genesis IBRC India Ltd 21.6 Cr. 16.616.6/9.73 6.600.00 %54.8 %54.8 % 10.0
Shreeoswal Seeds & Chemicals Ltd 192 Cr. 21.055.8/20.0 4.130.00 %0.62 %9.84 % 2.00
Nath Bio-Genes (India) Ltd 337 Cr. 178264/1678.33 3391.13 %6.85 %6.23 % 10.0
Continental Seeds and Chemicals Ltd 42.7 Cr. 38.870.2/18.0 21.80.00 %10.0 %18.0 % 10.0
Industry Average264.50 Cr70.5862.1776.810.23%14.57%17.89%8.40

All Competitor Stocks of Nath Bio-Genes (India) Ltd

Quarterly Result

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales36.9654.91215.1115.2421.9427.21209.3921.7325.3044.92235.2822.5731.74
Expenses29.6543.88166.5810.4415.6548.47174.9116.9819.6840.84198.2617.4825.96
Operating Profit7.3111.0348.534.806.29-21.2634.484.755.624.0837.025.095.78
OPM %19.78%20.09%22.56%31.50%28.67%-78.13%16.47%21.86%22.21%9.08%15.73%22.55%18.21%
Other Income0.000.000.000.000.00-88.050.000.200.060.260.120.062.54
Interest2.102.732.662.782.702.472.882.752.961.532.762.442.84
Depreciation0.670.810.680.680.681.050.670.670.670.990.760.760.76
Profit before tax4.547.4945.191.342.91-112.8330.931.532.051.8233.621.954.72
Tax %6.39%4.67%0.62%8.21%3.44%-3.07%0.55%3.92%34.15%12.64%0.65%17.95%16.31%
Net Profit4.257.1444.911.232.81-116.2930.761.471.351.5933.401.603.96
EPS in Rs2.243.7623.630.651.48-61.1916.190.770.710.8417.580.842.08

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales97109136143127142171206246271230234335
Expenses8289102109103113131163191204193185283
Operating Profit15203435252940435567374952
OPM %15%18%25%24%19%20%24%21%22%25%16%21%16%
Other Income1111101222-8713
Interest244561010579111010
Depreciation5554431113333
Profit before tax9122626151730394957-633642
Tax %-1%4%5%4%6%3%2%1%-4%2%-6%3%
Net Profit9122425141629385056-673541
EPS in Rs5.757.3415.1815.878.8510.1715.4820.2226.5629.29-35.4318.5121.34
Dividend Payout %0%0%0%0%0%0%0%0%0%7%-6%11%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2012-20132013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)33.33%100.00%4.17%-44.00%14.29%81.25%31.03%31.58%12.00%-219.64%152.24%
Change in YoY Net Profit Growth (%)0.00%66.67%-95.83%-48.17%58.29%66.96%-50.22%0.54%-19.58%-231.64%371.88%

Nath Bio-Genes (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2012-2013 to 2022-2023.

Growth

Compounded Sales Growth
10 Years:6%
5 Years:4%
3 Years:-3%
TTM:7%
Compounded Profit Growth
10 Years:4%
5 Years:-1%
3 Years:-13%
TTM:7%
Stock Price CAGR
10 Years:1%
5 Years:-11%
3 Years:-14%
1 Year:-14%
Return on Equity
10 Years:8%
5 Years:7%
3 Years:6%
Last Year:6%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 8:00 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital16161616161919191919191919
Reserves416691105287450489539594523554592624
Borrowings192322597433587010193105108127
Other Liabilities678597877869801027510511415858
Total Liabilities143190226267455571646730790740793877829
Fixed Assets18171330207211232246247245244249251
CWIP0000000000000
Investments5555555555566
Other Assets120168208231243355409479538490544622572
Total Assets143190226267455571646730790740793877829

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +156-143-47-2391173875
Cash from Investing Activity +-16-2-17-4-4-20-14-10-20-3-27
Cash from Financing Activity +1-43059020616-22-2-10
Net Cash Flow-0-1-0539-2317-253438

Free Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow15.001.0011.0013.00-34.00-45.007.00-15.00-15.00-34.00-56.00-56.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days7095114130133175191159147136152139
Inventory Days3,8404,7434,388
Days Payable1,3091,406586
Cash Conversion Cycle70951141302,6653,5121911591471363,954139
Working Capital Days167179242383398515544519585573578498
ROCE %24%33%26%14%10%9%8%9%10%5%7%7%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
Promoters41.03%41.05%41.07%45.59%45.59%45.59%45.59%45.59%45.59%45.59%45.59%45.59%
FIIs0.04%0.07%0.11%0.01%0.15%0.13%0.07%0.22%0.32%0.27%0.21%0.18%
DIIs7.17%4.85%4.62%4.62%4.62%4.62%4.62%4.37%4.37%4.37%4.37%4.37%
Public51.76%54.02%54.20%49.77%49.62%49.65%49.71%49.81%49.72%49.76%49.80%49.83%
No. of Shareholders33,92635,61035,48435,47034,74933,96033,50234,36534,26335,13235,83435,423

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Aditya Birla Sun Life Pure Value Fund828,5950.3216.53828,5952024-11-120%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 13Mar 12
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)19.5218.43-35.557.345.75
Diluted EPS (Rs.)19.5218.43-35.557.345.75
Cash EPS (Rs.)22.5620.01-33.8410.168.69
Book Value[Excl.RevalReserv]/Share (Rs.)320.94301.60285.1635.9128.57
Book Value[Incl.RevalReserv]/Share (Rs.)320.94301.60285.1635.9128.57
Revenue From Operations / Share (Rs.)175.03158.58146.4786.0477.43
PBDIT / Share (Rs.)26.5725.9420.5412.8010.61
PBIT / Share (Rs.)24.8524.3618.929.987.67
PBT / Share (Rs.)21.8719.03-33.387.686.54
Net Profit / Share (Rs.)20.8518.42-35.467.345.75
NP After MI And SOA / Share (Rs.)20.8518.42-35.467.345.75
PBDIT Margin (%)15.1716.3514.0214.8713.70
PBIT Margin (%)14.1915.3512.9111.599.90
PBT Margin (%)12.4912.00-22.788.928.45
Net Profit Margin (%)11.9111.61-24.208.527.42
NP After MI And SOA Margin (%)11.9111.61-24.208.527.42
Return on Networth / Equity (%)6.496.10-12.4320.4320.12
Return on Capital Employeed (%)7.648.036.5926.5425.62
Return On Assets (%)4.504.41-9.117.427.67
Long Term Debt / Equity (X)0.010.000.000.020.01
Total Debt / Equity (X)0.180.180.170.310.19
Asset Turnover Ratio (%)0.390.390.001.050.00
Current Ratio (X)2.182.412.411.221.34
Quick Ratio (X)1.301.451.270.430.42
Dividend Payout Ratio (NP) (%)9.5910.85-5.640.000.00
Dividend Payout Ratio (CP) (%)8.869.99-5.910.000.00
Earning Retention Ratio (%)90.4189.15105.640.000.00
Cash Earning Retention Ratio (%)91.1490.01105.910.000.00
Interest Coverage Ratio (X)5.544.873.685.589.40
Interest Coverage Ratio (Post Tax) (X)4.974.463.024.206.87
Enterprise Value (Cr.)363.13336.48494.220.000.00
EV / Net Operating Revenue (X)1.091.121.780.000.00
EV / EBITDA (X)7.196.8312.660.000.00
MarketCap / Net Operating Revenue (X)0.990.891.460.000.00
Retention Ratios (%)90.4089.14105.640.000.00
Price / BV (X)0.540.460.740.000.00
Price / Net Operating Revenue (X)0.990.891.460.000.00
EarningsYield0.110.13-0.160.000.00

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Nath Bio-Genes (India) Ltd as of November 19, 2024 is: 177.92

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 19, 2024, Nath Bio-Genes (India) Ltd is Overvalued by 0.04% compared to the current share price 178.00

Intrinsic Value of Nath Bio-Genes (India) Ltd as of November 19, 2024 is: 170.30

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 19, 2024, Nath Bio-Genes (India) Ltd is Overvalued by 4.33% compared to the current share price 178.00

Last 5 Year EPS CAGR: -4.28%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The company has higher reserves (381.15 cr) compared to borrowings (68.62 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (188.23 cr) and profit (22.69 cr) over the years.
  1. The stock has a low average ROCE of 13.50%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 431.75, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 99.08, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Nath Bio-Genes (India) Ltd:
    1. Net Profit Margin: 11.91%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 7.64% (Industry Average ROCE: 14.57%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 6.49% (Industry Average ROE: 17.89%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 4.97
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.3
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 8.33 (Industry average Stock P/E: 62.17)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.18
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Nath Bio-Genes (India) Ltd. is a Public Limited Listed company incorporated on 14/07/1993 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L01110MH1993PLC072842 and registration number is 072842. Currently Company is involved in the business activities of Growing of non-perennial crops. Company’s Total Operating Revenue is Rs. 278.36 Cr. and Equity Capital is Rs. 19.00 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Seeds/Tissue Culture/Bio TechnologyNath House, Nath Road, Aurangabad Maharashtra 431005investor@nathbiogenes.com
http://www.nathbiogenes.com
Management
NamePosition Held
Mr. Satish KagliwalManaging Director
Mr. Madhukar DeshpandeDirector
Ms. Ashu JainDirector
Mrs. Jeevanlata KagliwalDirector
Mr. Vadla NagabhushanamDirector
Mr. Hitesh PurohitDirector
Mr. Akash KagliwalDirector

FAQ

What is the latest intrinsic value of Nath Bio-Genes (India) Ltd?

The latest intrinsic value of Nath Bio-Genes (India) Ltd as on 19 November 2024 is ₹177.92, which is 0.04% lower than the current market price of ₹178.00.

What is the Market Cap of Nath Bio-Genes (India) Ltd?

The Market Cap of Nath Bio-Genes (India) Ltd is 337 Cr..

What is the current Stock Price of Nath Bio-Genes (India) Ltd as on 19 November 2024?

The current stock price of Nath Bio-Genes (India) Ltd as on 19 November 2024 is ₹178.

What is the High / Low of Nath Bio-Genes (India) Ltd stocks in FY 2024?

In FY 2024, the High / Low of Nath Bio-Genes (India) Ltd stocks is 264/167.

What is the Stock P/E of Nath Bio-Genes (India) Ltd?

The Stock P/E of Nath Bio-Genes (India) Ltd is 8.33.

What is the Book Value of Nath Bio-Genes (India) Ltd?

The Book Value of Nath Bio-Genes (India) Ltd is 339.

What is the Dividend Yield of Nath Bio-Genes (India) Ltd?

The Dividend Yield of Nath Bio-Genes (India) Ltd is 1.13 %.

What is the ROCE of Nath Bio-Genes (India) Ltd?

The ROCE of Nath Bio-Genes (India) Ltd is 6.85 %.

What is the ROE of Nath Bio-Genes (India) Ltd?

The ROE of Nath Bio-Genes (India) Ltd is 6.23 %.

What is the Face Value of Nath Bio-Genes (India) Ltd?

The Face Value of Nath Bio-Genes (India) Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Nath Bio-Genes (India) Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE